A Population-Based Evaluation of Cervical Screening in the United States: 2008–2011
Authors:
- Jack CuzickJCJack Cuzick
- Orrin MyersOMOrrin Myers
- William C. HuntWHWilliam C. Hunt
- Michael RobertsonMRMichael Robertson
- Nancy E. JosteNJNancy E. Joste
- Philip E. CastlePCPhilip E. Castle
- Vicki B. BenardVBVicki B. Benard
- Cosette M. WheelerCWCosette M. Wheeler
- 1 May 2014
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 23 (5) , 765-773
Abstract
Background: Cervical screening consumes substantial resources, but little is known about utilization in the United States or compliance with guideline recommendations. Methods: To describe population screening coverage, utilization, and outcomes and examine time trends from 2008 to 2011, cervical cytology reports from women residing in New Mexico (981,063 tests from 511,381 women) were evaluated. Results: From 2008 to 2011 cervical screening utilization decreased at all ages, but especially in younger women, with a two-third reduction at ages 15 to 20 years. Ninety-four percent of women ages 25 to 29 years were screened within 48 months but coverage decreased at older ages to 69% at 45 to 49 years and 55% at 60 to 64 years. Intervals between screening tests were significantly longer in 2011 compared with 2008 [HR = 1.23; 95% confidence intervals (CI), 1.22–1.24], although the commonest rescreening interval was 13 months. In 2011, 91.9% of screening tests for women ages 21 to 65 years were negative, 6.6% showed minor abnormalities, and 1.0% high-grade abnormalities. High-grade abnormality rates were relatively constant over time, but minor abnormalities and atypical cells cannot rule out high-grade (ASC-H) were increasing. Conclusions: This population-based evaluation of cervical screening shows high coverage under the age of 40 years, but lower levels in older women. Screening under age 21 years is becoming less common and screening intervals are lengthening, reflecting updates in national screening guidelines. Impact: Assessment of cervical screening intervals and population outcomes is essential for accurately estimating the impact and effectiveness of changing recommendations and vaccination against human papilloma virus infections. Cancer Epidemiol Biomarkers Prev; 23(5); 765–73. ©2013 AACR.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- New roles for public health in cancer screeningCA: A Cancer Journal for Clinicians, 2012
- Cervical Cancer Screening in the United States and the Netherlands: A Tale of Two CountriesThe Milbank Quarterly, 2012
- Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached?International Journal of Cancer, 2011
- Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysisCancer Causes & Control, 2008
- 2006 consensus guidelines for the management of women with abnormal cervical cancer screening testsAmerican Journal of Obstetrics and Gynecology, 2007
- Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for ScreeningObstetrics & Gynecology, 2004
- American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and CancerCA: A Cancer Journal for Clinicians, 2002
- A Case-Control Study of Cervical Cytology before Diagnosis of Cervical Cancer in DenmarkInternational Journal of Epidemiology, 1988
- TRENDS IN MORTALITY FROM CERVICAL CANCER IN THE NORDIC COUNTRIES: ASSOCIATION WITH ORGANISED SCREENING PROGRAMMESThe Lancet, 1987